FDA Approves the First Eye-Specific Bevacizumab for Wet Macular Degeneration After Two Decades of Off-Label Use

The FDA has approved the first ophthalmic formulation of bevacizumab for wet age-related macular degeneration, closing a gap that has defined retina care for twenty years.

Outlook Therapeutics announced that Lytenava, generic name bevacizumab-vikg, was approved for neovascular age-related macular degeneration. The company expects a U.S. launch before the end of 2026 and anticipates 12 years of reference product exclusivity under the Biologics Price Competition and Innovation Act.